Argano has acquired Pharosity Consulting, adding specialized expertise in Gross-to-Net, government pricing, commercial contracting, and advanced analytics for pharmaceutical and biotechnology companies as the consultancy pushes further into life sciences transformation work.
The deal, announced January 27, is Argano’s eighth acquisition since it launched a strategic growth program in April 2025 and its twenty-fourth transaction since the company was founded in 2020. The transaction closed in December 2025.
Argano said the acquisition strengthens its ability to help pharmaceutical organizations modernize finance, revenue, and analytics operations in heavily regulated environments, where pricing rules, policy requirements, and data complexity can create operational friction and compliance risk. Pharosity, founded in 2015, brings a structured operating model focused on policy-driven processes and delivery methods designed to support revenue operations and scalable compliance programs.
Argano also positioned Pharosity as a complementary fit with Twelve Consulting Group, which joined Argano in 2025, and said the combined capabilities enhance its end-to-end offering spanning strategic advisory, advanced analytics, and enterprise technology for pharmaceutical manufacturers facing evolving regulatory and commercial demands.
As part of the announcement, Argano highlighted its broader portfolio across business applications, AI, cloud infrastructure, data integration, and performance management, framing the expanded life sciences platform as a way to optimize operating models while supporting more effective regulatory engagement and compliance.
Support: Bass, Berry & Simms served as legal advisor to Argano. Ernst & Young provided financial diligence advisory. KHSA and Wipfli served as financial advisors and Messerli Kramer served as legal advisor to Pharosity.
KEY QUOTES:
“As we move into 2026, Argano continues to build momentum through a disciplined acquisition strategy that is expanding both our scale and industry depth. Pharosity’s distinct specialization and proven team complement our platform well, and we’re excited to welcome them to Argano. This acquisition supports our continued focus on delivering AI-enabled high-performance operations for pharmaceutical organizations facing increasingly complex regulatory and data environments.”
Chip Register, Group CEO of Argano
“Joining Argano enables us to extend our reach while continuing to deliver the focused expertise our clients value. We are excited to scale within a platform that prioritizes precision, partnership, and sustainable outcomes, expanding what we can provide to our pharmaceutical clients as they navigate complexities and drive better results.”
Brian Barbash, Co-Founder of Pharosity
